MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Alder Biopharmaceuticals Company Profile (NASDAQ:ALDR)

Consensus Ratings for Alder Biopharmaceuticals (NASDAQ:ALDR) (?)
Ratings Breakdown: 5 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $52.00 (126.88% upside)

Analysts' Ratings History for Alder Biopharmaceuticals (NASDAQ:ALDR)
Show:
DateFirmActionRatingPrice TargetActions
6/9/2016Jefferies GroupReiterated RatingBuy$61.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/30/2016Brean CapitalReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/21/2016Wells FargoInitiated CoverageOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/29/2016Leerink SwannReiterated RatingOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/29/2016Credit SuisseReiterated RatingOutperform$40.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/28/2014 forward)
Earnings History for Alder Biopharmaceuticals (NASDAQ:ALDR)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/3/2016        
4/28/2016Q1($0.72)($0.76)$0.14 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/23/2016Q4($0.65)($0.60)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2015Q315($0.51)($0.62)$0.23 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/5/2015Q215($0.40)($0.46)$0.23 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2015Q115($0.39)($0.40)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/4/2015Q414$0.21($0.22)$5.70 million$6.40 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/3/2014Q314$0.05$0.88$14.84 million$38.75 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/5/2014Q2($0.25)($0.40)$5.00 million$4.70 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
6/18/2014Q1($5.38)$4.60 million$4.80 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Alder Biopharmaceuticals (NASDAQ:ALDR)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163($0.74)($0.66)($0.71)
Q2 20163($0.80)($0.62)($0.71)
Q3 20163($0.90)($0.71)($0.81)
Q4 20163($1.13)($0.75)($0.92)
(Data provided by Zacks Investment Research)
Dividend History for Alder Biopharmaceuticals (NASDAQ:ALDR)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Alder Biopharmaceuticals (NASDAQ:ALDR)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/13/2016Mark James LittonInsiderSell6,000$28.94$173,640.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/3/2016Jeffrey T L SmithVPSell16,090$30.20$485,918.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/1/2016John A LathamInsiderSell10,000$30.02$300,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/31/2016Mark James LittonInsiderSell25,000$30.05$751,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/27/2016John A LathamInsiderSell6,401$30.05$192,350.05View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/24/2016Randall C SchatzmanCEOSell10,000$28.02$280,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/18/2016Randall C SchatzmanCEOSell30,000$28.07$842,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/4/2016Mark James LittoninsiderSell25,000$31.40$785,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/4/2016Randall C. SchatzmanCEOSell10,000$31.47$314,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/1/2015Jeffrey T. L. SmithVPSell4,272$37.24$159,089.28View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/1/2015John A. LathaminsiderSell4,550$37.24$169,442.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/1/2015Randall C. SchatzmanCEOSell10,000$37.24$372,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/30/2015Stephen M DowDirectorSell88$37.11$3,265.68View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/2/2015Jeffrey T. L. SmithVPSell3,900$33.67$131,313.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/2/2015John A. LathaminsiderSell4,545$33.69$153,121.05View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/2/2015Randall C. SchatzmanCEOSell10,000$33.71$337,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/1/2015Jeffrey T. L. SmithVPSell3,900$32.25$125,775.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/1/2015John A. LathaminsiderSell4,545$32.26$146,621.70View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/1/2015Jeffrey T. L. SmithVPSell3,900$38.50$150,150.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/1/2015John A. LathaminsiderSell4,545$38.52$175,073.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/31/2015Stephen M DowDirectorSell16,218$38.75$628,447.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/12/2015Larry BenedictVPSell25,454$47.46$1,208,046.84View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/4/2015John A LathamInsiderSell25,000$44.18$1,104,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/1/2015Jeffrey T L SmithVPSell3,900$41.53$161,967.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/1/2015John A LathamInsiderSell4,545$41.53$188,753.85View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/22/2015Jeffrey T L SmithVPSell61,818$38.86$2,402,247.48View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/21/2015Stephen M DowDirectorSell20,000$65.69$1,313,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/20/2015Stephen M DowDirectorSell8,462$40.39$341,780.18View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/18/2015Clay B SiegallDirectorSell38,181$37.62$1,436,369.22View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/1/2015Jeffrey T L SmithVPSell3,900$27.43$106,977.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/1/2015John A LathamInsiderSell19,045$29.54$562,589.30View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/30/2015John A LathamInsiderSell14,500$30.20$437,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/27/2015Jeffrey T L SmithVPSell3,900$28.01$109,239.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/27/2015John A LathamInsiderSell15,045$28.33$426,224.85View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/27/2015Randall C SchatzmanCEOSell100,000$28.42$2,842,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/26/2015Jeffrey T L SmithVPSell2,700$27.89$75,303.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/26/2015Mark James LittonInsiderSell5,200$28.03$145,756.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/26/2015Randall C SchatzmanCEOSell36,422$27.93$1,017,266.46View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/24/2014Jeffrey T L SmithVPSell29,090$16.08$467,767.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/13/2014A/S NovoInsiderBuy550,000$10.00$5,500,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/13/2014Alan Bruce MontgomeryDirectorBuy3,000$10.00$30,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/13/2014West 8 Limited Partne VenturesMajor ShareholderBuy250,000$10.00$2,500,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Alder Biopharmaceuticals (NASDAQ:ALDR)
DateHeadline
06/25/16 02:25 PMStock Tracing Lower on the Week Alder Biopharmaceuticals Inc. (NASDAQ:ALDR) - Engelwood Daily
06/25/16 02:25 PMStrong Sell Calls Recommendations For Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR) At 0 - Investor Newswire
06/25/16 02:25 PMAnalysts Spotlight: Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR) , Fibrocell Science Inc (NASDAQ:FCSC) - Street Updates
06/23/16 03:53 PMAlder BioPharmaceuticals Inc. (ALDR) Drops 6.78% on June 21 - Equities.com
06/21/16 02:22 PMRecently Issued Stock Ratings For Alder BioPharmaceuticals, Inc. (ALDR) - Fiscal Standard
06/20/16 02:24 PMStock on Trader's Radar: Alder Biopharmaceuticals Inc. (NASDAQ:ALDR) - iStreetWire
06/20/16 08:54 AMStock on Trader’s Radar: Alder Biopharmaceuticals Inc. (NASDAQ:ALDR)
06/19/16 07:10 AMStrong Buy Calls Count For Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR) At 4 - Investor Newswire
06/14/16 07:12 AMRecent Update on Price Movements: Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR) , Great Basin Scientific, Inc ... - Street Updates
06/10/16 08:09 PMAlder BioPharma (ALDR) to Present ALD403 Phase 1, Phase 2b Data at AHS Meeting
06/10/16 08:09 PMAlder Biopharmaceuticals Inc (NASDAQ:ALDR) ALD403 Meets Trial Targets
06/10/16 02:26 PMAlder Biopharmaceuticals Inc (ALDR) ALD403 Meets Trial Targets - Insider Monkey (blog)
06/10/16 01:41 PMAlder Biopharmaceuticals Inc (ALDR) ALD403 Meets Trial Targets -
06/10/16 10:48 AMAlder BioPharma (ALDR) to Present ALD403 Phase 1, Phase 2b Data at AHS Meeting - StreetInsider.com
06/09/16 07:09 AMAlder Presents Positive Clinical Data for ALD403 at the Annual Meeting of the American Headache Society - [at noodls] - BOTHELL, Wash., June 09, 2016 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced the ...
06/09/16 07:03 AM8:03 am Alder BioPharmaceuticals presents 'positive' clinical data for ALD403 at American Headache Society -
06/07/16 07:59 PMAlder BioPharmaceuticals Inc. (ALDR) Jumps 7.46% on June 06 - Equities.com
06/07/16 02:26 PMAlder BioPharma (ALDR) Names New Neurology VP - StreetInsider.com
06/07/16 10:48 AMAlder BioPharmaceuticals Appoints Roger Cady, M.D., Vice President of Neurology - GlobeNewswire (press release)
06/06/16 11:08 AMDELTA DRONE is in exclusive discussions for the purchase of ROCKETMINE (South Africa) - [at noodls] - Delta Drone and PDT - Public Display Technologies (PTY) Ltd have entered into an exclusive agreement with a view of Delta Drone to acquire sole ownership of ROCKETMINE, a subsidiary of PDT based in Johannesburg ...
06/06/16 07:18 AMAlder BioPharmaceuticals Appoints Roger Cady, M.D., Vice President of Neurology - [at noodls] - BOTHELL, Wash., June 06, 2016 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced the ...
06/05/16 08:18 AMSubscription of two blocks of 1 million euros each under the February 2015 contract for convertible notes with attached warrants - [at noodls] - * These calculations have been made based on the lowest of the Volume Weighted Average Price observed for the five trading days prior to 3 June 2016 (i.e., €1.2659) and on the basis of the current number ...
06/04/16 10:51 AMAnalyst Ratings on: Alder Biopharmaceuticals Inc. (NASDAQ:ALDR), Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) - Beacon Chronicle
06/04/16 10:51 AM10000 Shares of Alder Biopharmaceuticals Inc (ALDR) Stock are sold by John A. Latham - Let Me Know About This
06/03/16 06:12 AMBiotech picks: ALDR & RDHE -
06/02/16 08:22 PMAlder BioPharmaceuticals Inc. (ALDR) Jumps 6.11% on June 02 - Equities.com - The Point ReviewAlder BioPharmaceuticals Inc. (ALDR) Jumps 6.11% on June 02Equities.comAlder BioPharmaceuticals Inc. (ALDR) was among the biggest gainers on the Russell 2000 for Thursday June 02 as the stock popped 6.11% to $31.95, representing a gain of $1.84 per share. Some 944,748 shares traded hands on 7,446 trades, compared ...On the Move Insider Trading: Alder Biopharmaceuticals Inc (NASDAQ:ALDR)The Point ReviewAlder Biopharmaceuticals Inc (ALDR) Files Form 4 Insider Selling : Mark James Litton Sells 25000 SharesMarket DigestAlder Biopharmaceuticals Inc.: Alder Announces Presentations at Annual Meeting of the American Headache Society ...The Wall Street TranscriptNasdaqall 6 news articles »
06/02/16 11:03 AMOn the Move Insider Trading: Alder Biopharmaceuticals Inc (NASDAQ:ALDR) - The Point Review - The Point ReviewOn the Move Insider Trading: Alder Biopharmaceuticals Inc (NASDAQ:ALDR)The Point ReviewAlder Biopharmaceuticals Inc (NASDAQ:ALDR) insiders have most recently took part in a trading activity. On 5/24/2016 Schatzman Randall C, President and CEO sold 4,017 shares having total worth of $112,588 at the price of $28.03 per share, following the ...Alder Biopharmaceuticals Inc (ALDR) Files Form 4 Insider Selling : Mark James Litton Sells 25000 SharesMarket DigestAlder Biopharmaceuticals Inc (ALDR) is Trading Higher on Unusual Volume for May 31Equities.comInteresting ALDR Put And Call Options For January 2017NasdaqPharmiWeb.com (press release)all 5 news articles »
06/02/16 07:15 AMAlder Announces Presentations at Annual Meeting of the American Headache Society Supporting Development of ALD403 for Migraine Prevention - [at noodls] - BOTHELL, Wash., June 02, 2016 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced that ...
06/01/16 03:58 PMAlder Biopharmaceuticals, Inc. :ALDR-US: Earnings Analysis: Q1, 2016 By the Numbers : June 1, 2016 -
05/31/16 02:29 PMAlder Biopharmaceuticals Inc. (NASDAQ:ALDR) went down -0.85%: CPI Aerostructures Inc. (NYSEMKT:CVU), Baidu ... - KC Register - Alder Biopharmaceuticals Inc. (NASDAQ:ALDR) went down -0.85%: CPI Aerostructures Inc. (NYSEMKT:CVU), Baidu ...KC RegisterOn 25 May, Alder Biopharmaceuticals Inc. (NASDAQ:ALDR) announced the expansion of its leadership team to support the advancement of ALD403 for migraine prevention. Iqbal Husain, Ph.D., was appointed vice president of program and portfolio ...
05/31/16 08:24 AMContraFect Corporation (NASDAQ:CFRX) surged 14.83%: Alder Biopharmaceuticals Inc. (NASDAQ:ALDR ... - KC Register - ContraFect Corporation (NASDAQ:CFRX) surged 14.83%: Alder Biopharmaceuticals Inc. (NASDAQ:ALDR ...KC RegisterAlder Biopharmaceuticals Inc. (NASDAQ:ALDR) announced that it will webcast its presentation at the upcoming Jefferies 2016 Healthcare Conference at 9:30 a.m. ET on Tuesday, June 7, 2016 in New York, NY. The presentation will feature a business ...and more »
05/28/16 06:52 PMNew Leaf Venture Partners LLC Decreased Stake in Alder Biopharmaceuticals INC (NASDAQ:ALDR) by $6.06 Million ... - CCH Daily News - New Leaf Venture Partners LLC Decreased Stake in Alder Biopharmaceuticals INC (NASDAQ:ALDR) by $6.06 Million ...CCH Daily NewsRobert Boucai decreased its stake in Alder Biopharmaceuticals Inc (NASDAQ:ALDR) by 50.48% based on its latest 2016Q1 regulatory filing with the SEC. New Leaf Venture Partners Llc sold 252,592 shares as the company's stock declined 22.99% while ...Is it Time to Cash in Profits on Alder Biopharmaceuticals Inc. (NASDAQ:ALDR)Franklin Independentall 2 news articles »
05/27/16 04:27 PMALDER BIOPHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
05/26/16 07:09 PMTwo Stocks to Track: Emergent Biosolutions, Inc. (NYSE:EBS) , Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR) - Street Updates - Two Stocks to Track: Emergent Biosolutions, Inc. (NYSE:EBS) , Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR)Street UpdatesAlder BioPharmaceuticals, Inc. (NASDAQ:ALDR) moved in red zone with decline of -0.62 points or -2.19% to $27.74. The company has a market worth of $1.39B.Total 451.15 thousand shares were exchanged in last trading session as opposed to average ...and more »
05/26/16 07:09 PMHealthcare Stocks That Must Be on Your Watch List: Alder Biopharmaceuticals Inc (NASDAQ:ALDR) - The Point Review - The Point ReviewHealthcare Stocks That Must Be on Your Watch List: Alder Biopharmaceuticals Inc (NASDAQ:ALDR)The Point ReviewShare of Alder Biopharmaceuticals Inc (NASDAQ:ALDR) traded on 7.57 percent above secure line at 3:14PM EDT in order to take the company's stock at the price of $29.84. At the time of writing the stock exchanged hands 778,651 shares versus average ...Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR) Closes At $27.74Investor NewswireCormorant Asset Management LLC Increased Alder Biopharmaceuticals INC (NASDAQ:ALDR) by $17.76 Million as ...CCH Daily NewsAlder BioPharmaceuticals to Present at Two Upcoming June EventsGlobeNewswire (press release)all 5 news articles »
05/26/16 07:27 AMAlder BioPharmaceuticals to Present at Two Upcoming June Events - [at noodls] - BOTHELL, Wash., May 26, 2016 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced that ...
05/25/16 07:16 AMAlder BioPharmaceuticals Continues to Strengthen and Expand Leadership Team to Support Advancement of ALD403 for Migraine Prevention - [at noodls] - Iqbal Husain, Ph.D., Appointed Vice President of Program and Portfolio Management Dauphine S. Barone Promoted to Vice President of Manufacturing Logistics Barbara A. Schaeffler, MBA, Promoted to Vice President ...
05/22/16 11:41 AMAlder Biopharmaceuticals Inc's Trend Up, Especially After Today's Strong Session - Wall Street Hints and News - Alder Biopharmaceuticals Inc's Trend Up, Especially After Today's Strong SessionWall Street Hints and NewsThe stock of Alder Biopharmaceuticals Inc (NASDAQ:ALDR) is a huge mover today! The stock increased 5.07% or $1.35 on May 20, hitting $27.96. About 729,594 shares traded hands. Alder Biopharmaceuticals Inc (NASDAQ:ALDR) has declined 2.44% since ...
05/21/16 12:02 AMAlder Biopharmaceuticals Inc (ALDR) Jumps 5.07% on May 20 - Equities.com - Alder Biopharmaceuticals Inc (ALDR) Jumps 5.07% on May 20Equities.comAlder Biopharmaceuticals Inc (ALDR) was among the biggest gainers on the Russell 2000 for Friday May 20 as the stock popped 5.07% to $27.96, representing a gain of $1.35 per share. Some 727,897 shares traded hands on 6,922 trades, compared with an ...
05/18/16 11:21 AMAlder Biopharmaceuticals Inc (ALDR) Jumps 6.12% on May 16 - Equities.com - Alder Biopharmaceuticals Inc (ALDR) Jumps 6.12% on May 16Equities.comAlder Biopharmaceuticals Inc (ALDR) was among the biggest gainers on the Russell 2000 for Monday May 16 as the stock popped 6.12% to $25.48, representing a gain of $1.47 per share. Some 811,375 shares traded hands on 6,256 trades, compared with ...Latest Analyst Ratings For Alder BioPharmaceuticals, Inc. (ALDR)Share Trading Newsall 2 news articles »
05/14/16 06:25 PMNotable Buzzers: Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) , Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR) - Street Updates - Notable Buzzers: Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) , Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR)Street UpdatesOn 5/13/2016, shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) rose +0.45% in trading session and finally closed at $139.74. The company most recent volume stood at 1.14 million shares as compared to average volume of 1.58 million shares.and more »
05/14/16 12:25 AMAlder Biopharmaceuticals Inc (ALDR) Drops 6.36% on May 12 - Equities.com - Alder Biopharmaceuticals Inc (ALDR) Drops 6.36% on May 12Equities.comAlder Biopharmaceuticals Inc (ALDR) was one of the Russell 2000's biggest losers for Thursday May 12 as the stock slid 6.36% to $23.99, a loss of $-1.63 per share. Starting at an opening price of $25.85 a share, the stock traded between $23.27 and $26 ...
05/12/16 07:29 PMAnalyst Earnings Report: Alder Biopharmaceuticals Inc (NASDAQ:ALDR) - News Oracle - Analyst Earnings Report: Alder Biopharmaceuticals Inc (NASDAQ:ALDR)News OracleLast Trade: The Company fell -1.91% and finished at $25.62. The daily volume was measured at 371,557.00 shares. The 52-week high of the share price is $54.90 and the 52-week low is $15.82. The company has a market cap of $1.28 Billion. Its latest ...Latest Analyst Ratings For Alder BioPharmaceuticals, Inc. (ALDR)Share Trading Newsall 2 news articles »
05/09/16 04:59 PMALDER BIOPHARMACEUTICALS INC Files SEC form 8-K, Other Events -
05/08/16 08:45 PMNext Weeks Broker Price Targets For Alder BioPharmaceuticals, Inc. (ALDR) - Share Trading News - Next Weeks Broker Price Targets For Alder BioPharmaceuticals, Inc. (ALDR)Share Trading News04/20/2016 – Brean Capital began new coverage on Alder BioPharmaceuticals, Inc. giving the company a “buy” rating. They now have a USD 45 price target on the stock. 03/29/2016 – Alder BioPharmaceuticals, Inc. had its “outperform” rating reiterated by ...
05/06/16 07:44 AMAlder BioPharmaceuticals to Present at Bank of America Merrill Lynch 2016 Health Care Conference - [at noodls] - BOTHELL, Wash., May 06, 2016 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced that ...
05/06/16 07:24 AMAlder BioPharmaceuticals Licenses Clazakizumab Rights to Vitaeris - [at noodls] - BOTHELL, Wash., and VANCOUVER, British Columbia, May 06, 2016 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody ...
05/05/16 12:04 PMALDER BIOPHARMACEUTICALS INC Financials -
05/02/16 06:37 AMEdited Transcript of ALDR earnings conference call or presentation 28-Apr-16 9:00pm GMT -
05/02/16 02:18 AMLatest Analyst Ratings For Alder BioPharmaceuticals, Inc. (ALDR) - Share Trading News - Latest Analyst Ratings For Alder BioPharmaceuticals, Inc. (ALDR)Share Trading News04/20/2016 – Brean Capital began new coverage on Alder BioPharmaceuticals, Inc. giving the company a “buy” rating. They now have a USD 45 price target on the stock. 03/29/2016 – Alder BioPharmaceuticals, Inc. had its “outperform” rating reiterated by ...
About Alder Biopharmaceuticals

Alder Biopharmaceuticals logoAlder Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops and focuses to commercialize therapeutic antibodies with the potential to transform current treatment paradigms. The Company has developed an antibody platform designed to select antibodies that have the potential to maximize efficacy, as well as speed of onset and durability of therapeutic response. The Company's pipeline includes ALD403, Clazakizumab and ALD1613. ALD403 is the Company's monoclonal antibody targeted to calcitonin gene-related peptide (CGRP) for migraine prevention. Clazakizumab is a monoclonal antibody that inhibits the pro-inflammatory cytokine interleukin-6 (IL-6), and is in development for both rheumatoid arthritis (RA) and psoriatic arthritis (PsA). ALD1613 is a monoclonal antibody that inhibits Adrenocorticotropic Hormone (ACTH), and is being developed for the treatment of Cushing's disease. It is also developing ALD403 program for migraine prevention.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: ALDR
  • CUSIP:
Key Metrics:
  • Previous Close: $24.50
  • 50 Day Moving Average: $27.67
  • 200 Day Moving Average: $26.37
  • P/E Ratio: N/A
  • P/E Growth: -0.32
  • Market Cap: $1.15B
  • Current Quarter EPS Consensus Estimate: $-3.25 EPS
Additional Links:
Alder Biopharmaceuticals (NASDAQ:ALDR) Chart for Tuesday, June, 28, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha